Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.

What symbol and exchange does Vogenx shares trade?

Vogenx trades on the NASDAQ stock market under the symbol VOGX.

What is Vogenx stock price doing today?

As of October 30, 2026, VOGX stock price climbed to $20.25 with 44,494 million shares trading.

How much is Vogenx worth?

VOGX has a market cap of $300.82 million. This is considered a Small Cap stock.

What are the top ETFs holding Vogenx?

The top ETF exchange traded funds that VOGX belongs to (by Net Assets): VXF, VTWO, VTWG, VTWV, VTHR.

What are the support and resistance levels for Vogenx (VOGX)?

VOGX support price is $17.86 and resistance is $21.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VOGX shares will trade within this expected range on the day.